British drug company GlaxoSmithKline and its French competitor Sanofi have decided to pool their efforts to launch a joint project to develop a vaccine against the emerging coronavirus and start mass production.
And GlaxoSmithKline and Sanofi are among the four global giants that dominate the vaccine market, alongside Pfizer and Merck.
“We are working on the implementation of our program at a very fast pace, and it usually takes about 10 years to develop the vaccine from scratch, but if the project succeeds, we plan to produce hundreds of millions of doses by the end of next year, which requires Very close coordination with regulatory authorities around the world
She added that the goal of the joint project is not profit, but rather to make the prospective vaccine affordable so that it is accessible to the public, and that the company intends to transfer the profits from the vaccine sales to support its supply to developing countries.
Under the agreement signed between the two companies, Sanofi will provide, as part of the project, anti-protein S, which is one of the main components of the outer shell of the Covid-19 virus, which gives it a coronary shape and is supposed to be targeted by the future vaccine.
GlaxoSmithKline will share its expertise in developing materials that help stimulate the immune system response to the vaccine and reduce the dose needed to form an immune response against the virus.
Sanofi has previously confirmed the participation of the US Department of Health’s Advanced Biomedical Research and Development Authority in funding its research to develop a vaccine against the emerging coronavirus, and the two companies have invited other domestic and international official agencies to support the project.
According to the World Health Organization, there are about 70 vaccines currently being developed in the world.